Механизмы иммуномодулирующего действиямезенхимных стволовых клеток
- Авторы: Иванюк, ДИ1, Турчин, ВВ1, Попандопуло, АГ1, Гринь ВК1
-
Учреждения:
- Институт неотложной и восстановительной хирургии им. В.К. Гусака НАМНУ, Донецк, Украина
- Выпуск: Том 6, № 2 (2011)
- Страницы: 27-31
- Раздел: Статьи
- Статья получена: 11.01.2023
- Статья опубликована: 15.06.2011
- URL: https://genescells.ru/2313-1829/article/view/121654
- DOI: https://doi.org/10.23868/gc121654
- ID: 121654
Цитировать
Полный текст
![Открытый доступ](https://genescells.ru/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://genescells.ru/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://genescells.ru/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
личные функции в организме, обладают высокой пролифе-
ративной активностью и мультипотентными свойствами,
то есть способны дифференцироваться в клетки мезодер-
мальной (остеобласты, хондроциты, адипоциты) и других
линий. МСК также способны (прямо и опосредованно) вза-
имодействовать практически со всеми клетками иммунной
системы посредством растворимых факторов и клеточно-
контактным взаимодействием и, таким образом, в значи-
тельной степени модулировать иммунный ответ организма.
МСК могут найти своё применение в медицинской практике
как безопасное иммуномодулирующее средство при алло-
генных трансплантациях и лечении ряда аутоиммунных за-
болеваний. В данном обзоре обсуждаются взаимодействие
МСК с клетками иммунной системы, а также механизмы
МСК-индуцированной иммуносупрессии.
Об авторах
Д И Иванюк,
Институт неотложной и восстановительной хирургии им. В.К. Гусака НАМНУ, Донецк, УкраинаИнститут неотложной и восстановительной хирургии им. В.К. Гусака НАМНУ, Донецк, Украина
В В Турчин,
Институт неотложной и восстановительной хирургии им. В.К. Гусака НАМНУ, Донецк, УкраинаИнститут неотложной и восстановительной хирургии им. В.К. Гусака НАМНУ, Донецк, Украина
А Г Попандопуло,
Институт неотложной и восстановительной хирургии им. В.К. Гусака НАМНУ, Донецк, УкраинаИнститут неотложной и восстановительной хирургии им. В.К. Гусака НАМНУ, Донецк, Украина
В К Гринь
Институт неотложной и восстановительной хирургии им. В.К. Гусака НАМНУ, Донецк, УкраинаИнститут неотложной и восстановительной хирургии им. В.К. Гусака НАМНУ, Донецк, Украина
Список литературы
- Pittenger M.F., Mackay A.M., Beck S.C. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7.
- Le Blanc K., Frassoni F., Ball L. at al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-86.
- Sun L., Akiyama K., Zhang H. at al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27(6): 1421-32.
- Liang J., Zhang H., Hua B. at al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Multiple Sclerosis 2009; 15(5): 644-6.
- DelaRosa O., Lombardo E., Beraza A. at al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng. 2009; 15(10): 2795-806.
- Zappia E., Casazza S., Pedemonte E. at al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106: 1755-61.
- Sheng H., Wang Y., Jin Y. at al. A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Research 2008; 18: 846-57.
- Liotta F., Angeli R., Cosmi L. at al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26(1): 279-89
- English K., Ryan J.M., Tobin L. at al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 2009; 156(1): 149-60.
- Nemeth K., Leelahavanichkul A., Yuen P.S. at al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009; 15(1): 42-9.
- Yang S.H., Park M.J., Yoon I.H. at al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp. Mol. Med. 2009; 41(5): 315-24.
- Zhao Z.G., Li W.M., Chen Z.C. et al. Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia. Immunol. Invest. 2008; 37(7): 726-39.
- Sato K., Ozaki K., Oh I. at al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells Blood 2007; 109(1): 228-34.
- Ren G., Zhang L., Zhao X. at al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50.
- Chabannes D., Hill M., Merieau E. at al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110: 3691-4. 14. Selmani Z., Naji A., Zidi I. at al. Human leukocyte
- Selmani Z., Naji A., Zidi I. at al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-22.
- Honczarenko M., Le Y., Swierkowski M. at al. Human BMSC express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24: 1030-41.
- Selmani Z., Naji A., Gaiffe E. at al. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 2009; 87 Suppl 9: 62-6.
- Glennie S., Soeiro I., Dyson P.J. et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105(7): 2821-7.
- Ren G., Su J., Zhang L. at al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27(8): 1954-62.
- Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-22.
- Petrini I., Pacini S., Petrini M. at al. Mesenchymal cells inhibit expansion but not cytotoxicity exert
- Petrini I., Pacini S., Petrini M. at al. Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells. Eur. J. Clin. Invest. 2009; 39(9): 813-8.
- Rasmusson I., Ringden O., Sundberg B. et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-13
- Guo Z., Zheng C., Chen Z. at al. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. Eur. J. Immunol. 2009; 39(10): 2840-9.
- Rafei M., Campeau P.M., Aguilar-Mahecha A. at al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 2009; 182(10): 5994-6002.
- Nemeth K., Keane-Myers A., Brown J.M. at al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. PNAS USA 2010; 107(12): 5652-7.
- English K., Barry F.P., Field-Corbett C.P. et al. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 2007; 110(2): 91-100.
- Augello A., Tasso R., Negrini S.M. at al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 2005; 35(5): 1482-90.
- Ren G., Zhao X., Zhang L. at al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J. Immunol. 2010; 184(5): 2321-8.
- Krampera M., Cosmi L., Angeli R. at al. Role for interferongamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-98.
- Opitz C.A., Litzenburger U.M., Lutz C. at al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine- 2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009; 27(4): 909-19.
- Nemeth K., Mayer B., Mezey E. Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands. J. Mol. Med. 2010; 88(1): 5-10.
- Karlsson H., Samarasinghe S., Ball L.M. at al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008; 112(3): 532-41.
- Sotiropoulou P.A., Perez S.A., Gritzapis A.D. at al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
- Corcione A., Benvenuto F., Ferretti E. at al. Human mesenchymal stem cells modulate B-cell function. Blood 2006; 107: 367-72.
- Rafei M., Hsieh J., Fortier S. at al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008; 112: 4991-8.
- Djouad F., Charbonnier L.M., Bouffi C. at al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem cells 2007; 25: 2025-32.
- Jiang X.X., Zhang Y., Liu B. at al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105(10): 4120-26.
- Spaggiari G.M., Abdelrazik H., Becchetti F. at al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSCderived prostaglandin E2. Blood 2009; 113: 6576-83.
- Raffaghello L., Bianch G., Bertolotto M. at al. Human mesenchymal stem cells inhibit neutriphil apoptosis: a model for neutrophil preservation in the bone marrow nishe. Stem Cells 2008; 26: 151-62.
- Chan J.L., Tang K.C., Patel A.P. et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006; 107(12): 4817-24.
- Stagg J., Pommey S., Eliopoulos N. at al. IFNγ-stimulated marrow stromal cells: a new type of non-hematopoetic antigen presenting cells. Blood 2006; 107: 2570-77.
- Zangi L., Margalit R., Reich-Zeliger S. et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 2009; 27(11): 2865-74.
- Ortiz L.A., Dutreil M., Fattman C. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. PNAS USA 2007; 104(26): 11002-7. 45. Nemeth K., Keane-Myers A., Brown J. et al. Bone marrow
- Nemeth K., Keane-Myers A., Brown J. et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. PNAS USA 2010; 107(12): 5652-7.
- Boumaza I., Srinivasan S., Witt W.T. et al. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J. Autoimmun. 2009; 32(1): 33-42.
- Zheng Z.H., Li X.Y., Ding J. et al. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology 2008; 47(1): 22-30.
- Osiris Therapeutics Inc. PI Linda Custer. Prochymal™ adult human mesenchymal stem cells for treatment of moderate-to-severe Crohns disease. http://clinicaltrials.gov/ct2/show/NCT00294112?ter m=NCT00294112&rank=1
- The affiliated nanjing drum tower hospital of Nanjing university medical school (PI Lingyun Sun, MD). Allogeneic mesenchymal stem cells transplantation for primary Sjögrens syndrome (pSS). http://clinicaltrials. gov/ct2/show/NCT00953485?term=NCT00953485&rank=1
- Nanjing medical university, national natural science foundation of China (PI Lingyun Sun, MD). Mesenchymal stem cells transplantation for refractory systemic lupus erythematosus (SLE). http://clinicaltrials. gov/ct2/show/NCT00698191?term=NCT+00698191&rank=1
- The affiliated nanjing drum tower hospital of Nanjing university medical school (PI Lingyun Sun, MD). Allogeneic mesenchymal stem cells transplantation for systemic sclerosis (SSc). http://clinicaltrials. gov/ct2/results?term=NCT+00962923
- Tsuji H., Miyoshi S., Ikegami Y. et al. Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. Circ. Res. 2010; 106(10): 1613-23.
- Djouad, F., Plence P., Bony C. et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102(10): 3837-40.
- Karnoub A.E., Dash A.B., Vo A.P. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-63.
- Patel S.A., Meyer J.R., Greco S.J. et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J. Immunol. 2010; 184(10): 5885-94.
Дополнительные файлы
![](/img/style/loading.gif)